|DNA replication stress: causes, resolution and disease|
A Mazouzi, G Velimezi, JI Loizou
Experimental cell research 329 (1), 85-93, 2014
|Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer|
G Velimezi, M Liontos, K Vougas, T Roumeliotis, J Bartkova, M Sideridou, ...
Nature cell biology 15 (8), 967-977, 2013
|The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis|
K Evangelou, J Bartkova, A Kotsinas, IS Pateras, M Liontos, G Velimezi, ...
Cell Death & Differentiation 20 (11), 1485-1497, 2013
|Modulation of the E2F1-driven cancer cell fate by the DNA damage response machinery and potential novel E2F1 targets in osteosarcomas|
M Liontos, K Niforou, G Velimezi, K Vougas, K Evangelou, ...
The American journal of pathology 175 (1), 376-391, 2009
|ATMIN is required for the ATM-mediated signaling and recruitment of 53BP1 to DNA damage sites upon replication stress|
L Schmidt, M Wiedner, G Velimezi, J Prochazkova, M Owusu, S Bauer, ...
DNA repair 24, 122-130, 2014
|Loss of p14ARF confers resistance to heat shock‐and oxidative stress‐mediated cell death by upregulating β‐catenin|
A Damalas, G Velimezi, A Kalaitzakis, M Liontos, AG Papavassiliou, ...
International journal of cancer 128 (8), 1989-1995, 2011
|Map of synthetic rescue interactions for the Fanconi anemia DNA repair pathway identifies USP48|
G Velimezi, L Robinson-Garcia, F Muñoz-Martínez, WW Wiegant, ...
Nature communications 9 (1), 1-14, 2018
|Parallel genome-wide screens identify synthetic viable interactions between the BLM helicase complex and Fanconi anemia|
M Moder, G Velimezi, M Owusu, A Mazouzi, M Wiedner, JF da Silva, ...
Nature communications 8 (1), 1-8, 2017
|DNA repair cofactors ATMIN and NBS1 are required to suppress T cell activation|
J Prochazkova, S Sakaguchi, M Owusu, A Mazouzi, M Wiedner, ...
PLoS Genet 11 (11), e1005645, 2015
|The roles of p27Kip1 and DNA damage signalling in the chemotherapy‐induced delayed cell cycle checkpoint|
M Liontos, G Velimezi, IS Pateras, R Angelopoulou, AG Papavassiliou, ...
Journal of cellular and molecular medicine 14 (9), 2264-2267, 2010
|Is exclusive Skp2 targeting always beneficial in cancer therapy?|
M Koutsami, G Velimezi, A Kotsinas, K Evangelou, AG Papavassiliou, ...
Blood, The Journal of the American Society of Hematology 112 (12), 4777-4779, 2008
|Response: Human memory but not naïve γδ T cells from TST-positive individuals respond to M tuberculosis antigen|
L Li, CY Wu
Blood 112 (12), 4777, 2008